Form 4: Protagonist Therapeutics Director Exercises Stock Options

Harold E. Selick, a director of Protagonist Therapeutics, exercised stock options to acquire 10,725 shares of common stock at $1.16 per share on April 28, 2025.

Summary

• On April 28, 2025, Harold E. Selick, a director of Protagonist Therapeutics, Inc., exercised stock options.
• This transaction involved the acquisition of 10,725 shares of common stock at a price of $1.16 per share.
• Following the transaction, Mr. Selick beneficially owns 43,851 shares of Protagonist Therapeutics common stock.
• The stock options were fully vested and the transaction was reported on April 30, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a standard transaction. The exercise of options could be seen as a positive sign, but it's a routine event.

Positives

• The exercise of vested stock options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates a director's activity in the company's stock.

Stakeholder Impact

• The transaction may have a minor impact on shareholders by slightly increasing the number of outstanding shares.

Key Dates

Keywords

Protagonist Therapeutics, Director, Stock Options, Beneficial Ownership, Form 4, PTGX, Selick